Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADUS Addus HomeCare	$109.69 +1.2%	$112.53	$88.96 ▼ $136.72	$2.02B	0.81	165,968 shs	138,793 shs
GH Guardant Health	$47.28 -1.1%	$46.10	$20.14 ▼ $53.42	$5.86B	1.44	2.17 million shs	2.86 million shs
OPCH Option Care Health	$29.94 -1.5%	$31.66	$21.39 ▼ $35.53	$4.90B	0.73	1.83 million shs	1.62 million shs
RDNT RadNet	$58.84 +2.8%	$57.26	$45.00 ▼ $93.65	$4.41B	1.41	686,182 shs	1.04 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADUS Addus HomeCare	-0.90%	-5.22%	-5.24%	+7.10%	-11.72%
GH Guardant Health	-0.58%	-6.33%	-3.02%	+6.32%	+41.32%
OPCH Option Care Health	-1.14%	-0.82%	-4.49%	-5.28%	-2.69%
RDNT RadNet	+3.25%	-0.62%	-0.30%	+15.03%	-12.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADUS Addus HomeCare	4.9671 of 5 stars	3.6	4.0	5.0	3.4	2.5	3.1
GH Guardant Health	4.5853 of 5 stars	3.5	3.0	4.4	3.9	2.5	0.6
OPCH Option Care Health	4.4454 of 5 stars	2.4	5.0	4.3	2.5	1.7	1.9
RDNT RadNet	3.4586 of 5 stars	2.8	2.0	4.6	1.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADUS Addus HomeCare	3.25	Buy	$142.57	29.98% Upside
GH Guardant Health	3.05	Buy	$53.76	13.71% Upside
OPCH Option Care Health	2.88	Moderate Buy	$35.50	18.57% Upside
RDNT RadNet	3.50	Strong Buy	$69.60	18.29% Upside

Current Analyst Ratings Breakdown

Latest ADUS, GH, OPCH, and RDNT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	ADUS Addus HomeCare	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$150.00
7/14/2025	GH Guardant Health	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	RDNT RadNet	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$74.00
7/10/2025	OPCH Option Care Health	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$38.00
6/20/2025	ADUS Addus HomeCare	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$150.00
6/18/2025	OPCH Option Care Health	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$36.00
6/13/2025	GH Guardant Health	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $65.00
6/13/2025	RDNT RadNet	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$69.00
6/12/2025	RDNT RadNet	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy
6/10/2025	ADUS Addus HomeCare	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$133.00
5/8/2025	ADUS Addus HomeCare	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$129.00 ➝ $133.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADUS Addus HomeCare	$1.15B	1.75	$5.40 per share	20.30	$53.52 per share	2.05
GH Guardant Health	$739.02M	7.93	N/A	N/A	($1.13) per share	-41.84
OPCH Option Care Health	$5.00B	0.98	$1.60 per share	18.69	$8.25 per share	3.63
RDNT RadNet	$1.87B	2.36	$3.70 per share	15.92	$15.31 per share	3.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADUS Addus HomeCare	$73.60M	$4.43	24.76	20.46	1.55	6.52%	9.23%	6.96%	8/4/2025 (Estimated)
GH Guardant Health	-$436.37M	-$3.39	N/A	N/A	N/A	-53.82%	N/A	-26.77%	7/30/2025 (Estimated)
OPCH Option Care Health	$211.82M	$1.24	24.15	23.76	1.86	4.12%	16.90%	7.00%	7/30/2025 (Estimated)
RDNT RadNet	$2.79M	-$0.43	N/A	111.02	N/A	-1.73%	1.41%	0.48%	8/6/2025 (Estimated)

Latest ADUS, GH, OPCH, and RDNT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	GH Guardant Health	-$0.52	N/A	N/A	N/A	$211.19 million	N/A
8/6/2025	Q2 2025	RDNT RadNet	$0.17	N/A	N/A	N/A	$488.06 million	N/A
8/4/2025	Q2 2025	ADUS Addus HomeCare	$1.45	N/A	N/A	N/A	$345.71 million	N/A
7/30/2025	Q2 2025	OPCH Option Care Health	$0.40	N/A	N/A	N/A	$1.35 billion	N/A
5/5/2025	Q1 2025	ADUS Addus HomeCare	$1.33	$1.42	+$0.09	$1.16	$341.66 million	$337.71 million
4/30/2025	Q1 2025	GH Guardant Health	-$0.57	-$0.49	+$0.08	-$0.77	$189.91 million	$203.47 million
4/29/2025	Q1 2025	OPCH Option Care Health	$0.36	$0.40	+$0.04	$0.28	$1.26 billion	$1.33 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADUS Addus HomeCare	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
OPCH Option Care Health	N/A	N/A	N/A	N/A	N/A
RDNT RadNet	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADUS Addus HomeCare	0.20	1.74	1.74
GH Guardant Health	N/A	4.11	3.76
OPCH Option Care Health	0.82	1.54	1.02
RDNT RadNet	0.87	2.01	2.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADUS Addus HomeCare	95.35%
GH Guardant Health	92.60%
OPCH Option Care Health	98.05%
RDNT RadNet	77.90%

Insider Ownership

Company	Insider Ownership
ADUS Addus HomeCare	4.60%
GH Guardant Health	6.10%
OPCH Option Care Health	0.64%
RDNT RadNet	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADUS Addus HomeCare	49,703	18.40 million	17.55 million	Optionable
GH Guardant Health	2,021	123.89 million	116.33 million	Not Optionable
OPCH Option Care Health	8,088	163.75 million	162.70 million	Optionable
RDNT RadNet	11,021	75.03 million	70.83 million	Optionable

ADUS, GH, OPCH, and RDNT Headlines

Recent News About These Companies

RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

2 hours ago | finance.yahoo.com

RadNet Completes Acquisition of iCAD for AI Expansion

3 hours ago | tipranks.com

RadNet, Inc. (NASDAQ:RDNT) Shares Purchased by Segall Bryant & Hamill LLC

July 17 at 6:51 AM | marketbeat.com

56,263 Shares in RadNet, Inc. (NASDAQ:RDNT) Acquired by Edgestream Partners L.P.

July 17 at 5:17 AM | marketbeat.com

Cerity Partners LLC Has $7.42 Million Holdings in RadNet, Inc. (NASDAQ:RDNT)

July 16 at 4:06 AM | marketbeat.com

Enhanced Breast Cancer Detection: RadNet’s AI-Powered gives providers new insight

July 14 at 5:34 AM | ladowntownnews.comL

Emerald Advisers LLC Cuts Stock Position in RadNet, Inc. (NASDAQ:RDNT)

July 13, 2025 | marketbeat.com

RadNet, Inc. (NASDAQ:RDNT) Receives $69.60 Consensus Price Target from Brokerages

July 13, 2025 | americanbankingnews.com

Critical Review: RadNet (NASDAQ:RDNT) and Ceres Ventures (OTCMKTS:CEVE)

July 13, 2025 | americanbankingnews.com

RadNet, Inc. (NASDAQ:RDNT) Receives Consensus Recommendation of "Strong Buy" from Brokerages

July 10, 2025 | marketbeat.com

RadNet (RDNT) Stock Trades Up, Here Is Why

July 10, 2025 | msn.com

Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group Add RadNet's AI-Powered Enhanced Breast Cancer Detection (EBCD) Program to its Membership Benefits in Southern California

July 9, 2025 | globenewswire.com

Penserra Capital Management LLC Buys 59,018 Shares of RadNet, Inc. (NASDAQ:RDNT)

July 7, 2025 | marketbeat.com

Calamos Advisors LLC Sells 16,087 Shares of RadNet, Inc. (NASDAQ:RDNT)

July 6, 2025 | marketbeat.com

Principal Financial Group Inc. Has $66.16 Million Stock Position in RadNet, Inc. (NASDAQ:RDNT)

July 6, 2025 | marketbeat.com

Palisade Capital Management LP Invests $3.99 Million in RadNet, Inc. (NASDAQ:RDNT)

July 4, 2025 | marketbeat.com

The 5 Most Interesting Analyst Questions From RadNet’s Q1 Earnings Call

July 2, 2025 | msn.com

Q1 Earnings Highs And Lows: RadNet (NASDAQ:RDNT) Vs The Rest Of The Testing & Diagnostics Services Stocks

July 2, 2025 | msn.com

Allspring Global Investments Holdings LLC Boosts Position in RadNet, Inc. (NASDAQ:RDNT)

June 29, 2025 | marketbeat.com

RadNet (NASDAQ:RDNT) Lowered to "Sell" Rating by Wall Street Zen

June 29, 2025 | marketbeat.com

Sequoia Financial Advisors LLC Takes Position in RadNet, Inc. (NASDAQ:RDNT)

June 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
Why Wall Street Is Betting on These 3 Comeback Stocks
By Nathan Reiff | July 12, 2025
View Why Wall Street Is Betting on These 3 Comeback Stocks
3 Stocks With Near-Unanimous Buys That Could Rally Higher
By Nathan Reiff | July 2, 2025
View 3 Stocks With Near-Unanimous Buys That Could Rally Higher
New All-Time Highs Coming for Broadcom? Wall Street Says Yes
By Leo Miller | June 20, 2025
View New All-Time Highs Coming for Broadcom? Wall Street Says Yes

ADUS, GH, OPCH, and RDNT Company Descriptions

Addus HomeCare NASDAQ:ADUS

$109.69 +1.25 (+1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$109.67 -0.02 (-0.02%)

As of 06:04 PM Eastern

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.

Guardant Health NASDAQ:GH

$47.28 -0.53 (-1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$47.74 +0.45 (+0.96%)

As of 07:14 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Option Care Health NASDAQ:OPCH

$29.94 -0.45 (-1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$30.55 +0.61 (+2.03%)

As of 05:07 PM Eastern

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

RadNet NASDAQ:RDNT

$58.84 +1.58 (+2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$59.42 +0.58 (+0.99%)

As of 06:47 PM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time